In late May 2026, ICON plc reported Q4 and full-year 2025 results showing modest revenue growth to US$2,112.52 million for the quarter and US$8.25 billion for the year, but a sharp drop in net income ...

Quarter four revenue was $2,112.5 million. Full year revenue was $8,251 million. Quarter four adjusted EBITDA of $327.1 ...

ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board ...

ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company' ...

ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, ...

New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas and Kansas will f ...

Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures are ...

ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, ...

Investigation’s preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal year DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) today announced ...

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, ...